1. Home
  2. CIGI vs RYTM Comparison

CIGI vs RYTM Comparison

Compare CIGI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Colliers International Group Inc. Subordinate Voting Shares

CIGI

Colliers International Group Inc. Subordinate Voting Shares

HOLD

Current Price

$94.02

Market Cap

5.8B

Sector

N/A

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$88.70

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIGI
RYTM
Founded
1972
2008
Country
Canada
United States
Employees
N/A
414
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.2B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
CIGI
RYTM
Price
$94.02
$88.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
14
Target Price
$176.25
$131.14
AVG Volume (30 Days)
305.5K
713.2K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
0.29%
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.28
$55.34
Revenue Next Year
$8.30
$86.06
P/E Ratio
$57.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$90.93
$58.71
52 Week High
$171.20
$122.20

Technical Indicators

Market Signals
Indicator
CIGI
RYTM
Relative Strength Index (RSI) 33.92 47.71
Support Level N/A $87.19
Resistance Level $120.37 $92.17
Average True Range (ATR) 4.26 4.91
MACD -1.01 0.15
Stochastic Oscillator 8.97 41.94

Price Performance

Historical Comparison
CIGI
RYTM

About CIGI Colliers International Group Inc. Subordinate Voting Shares

Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are Commercial Real Estate, Engineering and Investment Management. Maximum revenue for the company is generated from its Commercial Real Estate segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, and others. Geographically, the company generates maximum revenue from the United States followed by Canada, Euro currency countries, Australia, the United Kingdom, Poland, China, India, and other regions.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: